As the current targeted drug for the treatment of metastatic colorectal cancer, it is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), which plays an antitumor effect by blocking the formation of tumor blood vessels and regulating the immune function of patients [36]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.